{"entity":{"id":"john-strickler","kind":"person","name":"John H. Strickler","aka":[],"tldr":"Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.","summary":"John Strickler is a gastrointestinal medical oncologist at Duke Cancer Institute. He was first author of the 2023 Lancet Oncology report of MOUNTAINEER, the phase 2 trial in which tucatinib plus trastuzumab produced durable responses in chemotherapy-refractory HER2-positive, RAS wild-type metastatic colorectal cancer, leading to accelerated approval. He also led early work on sotorasib in KRAS G12C colorectal cancer and studies ctDNA to guide therapy.","asOf":"2026-09-18","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["her2-amplified-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-mountaineer-lancet-oncol-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal medical oncologist, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["HER2-amplified colorectal cancer","Targeted therapy","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strickler%5BAuthor%5D"}],"papers":[],"orcid":"0000-0001-7579-1175"},"route":"/people/john-strickler/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"}],"institution":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/"}],"paper":[{"id":"paper-mountaineer-lancet-oncol-2023","kind":"paper","name":"MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer","route":"/key-papers/paper-mountaineer-lancet-oncol-2023/"}]}}